Natural peptide · 32 amino acids · 3,431.9 Da

Calcitonin-salmon studies and research data

PepBank has 133 calcitonin-salmon studies with results. 131 of them gave calcitonin-salmon, with 661 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 661 results and 1,643 papers. Newer studies from Europe PMC

Results in people

619

94% of 661 results

Results in animals

1% of 661 results

Results in lab cells

5% of 661 results

From computer models

0% of 661 results

The molecule

Calcitonin-salmon identity

Identifiers, parent molecule, targets and development stage, from curated data.

Calcitonin-salmon has the 32-residue sequence of salmon calcitonin. The medicinal peptide can be made synthetically. Nasal and injectable formulations have different indications and restrictions.

Kind: Natural peptide · 32 residues
Identifiers: ChEMBLCHEMBL3989767 (opens in a new tab)PubChem CID16133812 (opens in a new tab)UNII7SFC6U2VI5 (opens in a new tab)DrugBankDB00017 (opens in a new tab)CAS47931-85-1
Development: Approved in the US and EU (Calcitonin salmon nasal spray)Approved nasal products exist in the US. The cited label establishes approval, not approval for every studied indication or availability of every brand. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Calcitonin receptorCALCRP30988 (opens in a new tab)	Agonist	Official prescribing information, mechanism of actionSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

32 amino acids · 1 disulfide bond

H-

CSNLSTCVLG

KLSQELHKLQ

TYPRTNTGSG

Properties

From identity sources

Formula: C₁₄₅H₂₄₀N₄₄O₄₈S₂
Molecular weight: 3,431.9 g/mol
Monoisotopic mass: 3,429.7133 Da

GSRS UNII 7SFC6U2VI5(opens in a new tab)retrieved 2026-10-27
PubChem CID 16133812(opens in a new tab)retrieved 2026-10-27
Curated Calcitonin salmon nasal spray US label (Apotex)(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Average mass: 3,431.89 Da; Sum of ExPASy residue masses + water + C-amide, 1 disulfide · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 3,429.7133 Da; Sum of ExPASy residue masses + water + C-amide, 1 disulfide · ExPASy FindMod
Isoelectric point (pI): 10.90; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 3.05; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.538; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 1,490 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp: ExPASy reports more than 10 % error without Trp.
Extinction coefficient, 280 nm (all Cys as cystines): 1,615 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 17.84; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; 40 or below: classed as stable (ExPASy).
Aliphatic index: 70.0; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 1.70 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.604; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 10.90Bjellqvist (ExPASy) 10.29IPC peptide 10.72IPC protein 10.20

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 10.90 · Net charge at pH 7.4: 3.05

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set, C-amide, 1 disulfide. Calculated, not measured.

Show as table

pH	Net charge
0	5.00
1	5.00
2	4.99
3	4.93
4	4.55
5	4.08
6	3.77
7	3.22
8	2.82
9	2.18
10	1.32
11	−0.14
12	−1.11
13	−1.75
14	−1.97

Composition

Hydrophobic19% (6)L V
Aromatic3% (1)Y
Positive13% (4)H K R
Negative3% (1)E
Polar41% (13)N Q S T
Special22% (7)C G P

32 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%

I Ile0 · 0%

L Leu5 · 16%

M Met0 · 0%

V Val1 · 3%

F Phe0 · 0%

W Trp0 · 0%

Y Tyr1 · 3%

H His1 · 3%

K Lys2 · 6%

R Arg1 · 3%

D Asp0 · 0%

E Glu1 · 3%

N Asn2 · 6%

Q Gln2 · 6%

S Ser4 · 13%

T Thr5 · 16%

C Cys2 · 6%

G Gly3 · 9%

P Pro2 · 6%

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

2D structure

Calcitonin-salmon has 32 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 16133812(opens in a new tab)

C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CO)CC(C)C)CC(=O)N)CO)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N5CCC[C@H]5C(=O)N)O

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.222
μH, best 11-residue window: 0.604
Arrow direction: 19°
Residues: 32 · 2 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	C	0°	0.29
2	S	100°	-0.18
3	N	200°	-0.78
4	L	300°	1.06
5	S	40°	-0.18
6	T	140°	-0.05
7	C	240°	0.29
8	V	340°	1.08
9	L	80°	1.06
10	G	180°	0.48
11	K	280°	-1.50
12	L	20°	1.06
13	S	120°	-0.18
14	Q	220°	-0.85
15	E	320°	-0.74
16	L	60°	1.06
17	H	160°	-0.40
18	K	260°	-1.50
19	L	0°	1.06
20	Q	100°	-0.85
21	T	200°	-0.05
22	Y	300°	0.26
23	P	40°	0.12
24	R	140°	-2.53
25	T	240°	-0.05
26	N	340°	-0.78
27	T	80°	-0.05
28	G	180°	0.48
29	S	280°	-0.18
30	G	20°	0.48
31	T	120°	-0.05
32	P	220°	0.12

Results by area

Calcitonin-salmon results by year and outcome

Counts are exact and come from studies that gave the peptide.

Calcitonin-salmon has 1,643 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

Studies by year

133 of 1,643 studies have results (8.1%), published 1976 to 2021. Top row: every study. Bottom row: studies with results about Calcitonin-salmon, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies1,642 in all, 1969 to 2026

Studies with results133 in all, 1976 to 2021

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Calcitonin-salmon studies on bones and joints

361 results · people 346 · animals 4 · lab 11

Top 5 of 361 results

In women with postmenopausal osteoporosis, SMC021 did not prevent new vertebral fractures compared with placebo.Bone, 2016
In premenopausal and early postmenopausal women, serum calcium changed significantly after each of the four sCT administrations.The Journal of clinical endocrinology and metabolism, 1991
In CSMC021C2301, oral sCT with 5-CNAC carrier did not significantly affect joint space narrowing versus placebo.Osteoarthritis and cartilage, 2015
In normal subjects, inhaled calcitonin significantly reduced blood calcium.Calcified tissue international, 1997
In postmenopausal women with osteoporosis, salmon calcitonin nasal spray at 200 IU daily reduced new spine fracture risk by 33% versus placebo.The American journal of medicine, 2000

Calcitonin-salmon studies on side effects

55 results · people 55 · animals 0 · lab 0

Top 5 of 55 results

In women with postmenopausal osteoporosis, approximately 92% of both SMC021 and placebo groups had adverse events, mostly mild or moderate.Bone, 2016
In women with postmenopausal osteoporosis, nearly half in every group had gastrointestinal adverse events, the main reason for early withdrawal.Journal of bone and mineral research, 2012
In patients with malignant hypercalcemia, neither salmon calcitonin plus APD nor APD alone caused flushing.Archives of internal medicine, 1990
In women with osteoporosis, dizziness rates were numerically higher with salmon calcitonin than teriparatide, without statistical significance.Current medical research and opinion, 2006
In early postmenopausal women, nasal discomfort occurred in one salmon calcitonin recipient and one placebo recipient.Calcified tissue international, 1995

Calcitonin-salmon studies on pain

52 results · people 52 · animals 0 · lab 0

Top 5 of 52 results

In women with osteoporosis and back pain, salmon calcitonin improved pain more than placebo.Clinical rheumatology, 2007
In postoperative patients, salmon calcitonin plus lidocaine reduced pain more than lidocaine plus saline.Anesthesia and analgesia, 1987
In postmenopausal women with osteoporosis and back pain, pain effects did not differ significantly between salmon calcitonin with calcium and calcium alone.European spine journal, 2006
In women with osteoporosis and back pain, salmon calcitonin increased a natural pain-related peptide compared with placebo.Clinical rheumatology, 2007
In patients with reflex sympathetic dystrophy, salmon calcitonin reduced resting pain compared with placebo with physiotherapy.Pain, 1992

Calcitonin-salmon studies on blood levels and clearance

49 results · people 49 · animals 0 · lab 0

Top 5 of 49 results

In postmenopausal women, salmon calcitonin with 50 ml water doubled peak blood concentration compared with 200 ml water.BMC clinical pharmacology, 2008
In premenopausal and early postmenopausal women, plasma sCT rose significantly after most sCT doses, but not after 50 IU intranasal.The Journal of clinical endocrinology and metabolism, 1991
In healthy volunteers, aerosol salmon calcitonin lung doses ranged from 53 to 88 microgm.Pharmaceutical research, 2008
In postmenopausal women, morning salmon calcitonin concentration was 45 pg/ml, comparable to pre-dinner dosing.BMC clinical pharmacology, 2008
In premenopausal and early postmenopausal women, sCT exposure varied significantly with the dose.The Journal of clinical endocrinology and metabolism, 1991

Calcitonin-salmon studies on salt, water and minerals

37 results · people 37 · animals 0 · lab 0

Top 5 of 37 results

In cancer-related hypercalcemia, salmon calcitonin achieved normocalcemia less often than gallium nitrate.Annals of internal medicine, 1988
In postmenopausal osteoporosis, blood calcium was significantly lower with salmon calcitonin than control at 4 months.Metabolism: clinical and experimental, 1984
In normal subjects, salmon calcitonin reduced intestinal calcium absorption by 58% from basal conditions.The Journal of clinical endocrinology and metabolism, 1976
In psychiatric inpatients, salmon calcitonin decreased blood calcium in a trial with placebo.Archives of general psychiatry, 1979
In postmenopausal osteoporosis, urine calcium significantly increased during the first 4 months of salmon calcitonin therapy.Metabolism: clinical and experimental, 1984

Calcitonin-salmon studies on daily life and fitness

32 results · people 32 · animals 0 · lab 0

Top 5 of 32 results

In postmenopausal women with osteoporosis and back pain, disability effects did not differ significantly between salmon calcitonin with calcium and calcium alone.European spine journal, 2006
In women with osteoporosis and back pain, salmon calcitonin improved quality of life more than placebo.Clinical rheumatology, 2007
In patients with reflex sympathetic dystrophy, salmon calcitonin improved movement range compared with placebo with physiotherapy.Pain, 1992
In women with postmenopausal osteoporosis, quality of life did not change between SMC021 and placebo groups through month 36.Bone, 2016
Walking time to pain did not differ significantly between calcitonin and placebo.Spine, 2004

Calcitonin-salmon studies on receptors and cell signals

34 results · people 13 · animals 0 · lab 21

Top 5 of 34 results

In premenopausal and early postmenopausal women, serum beta-endorphin changed significantly after each of the four sCT administrations.The Journal of clinical endocrinology and metabolism, 1991
In volunteers, nasal and rectal salmon calcitonin were less effective than injected salmon calcitonin.Clinical orthopaedics and related research, 1987
In a subject with low parathyroid function, the intestinal response to salmon calcitonin occurred twice without endogenous parathyroid hormone involvement.The Journal of clinical endocrinology and metabolism, 1976
In mouse cell co-cultures treated with vitamin D, salmon calcitonin increased cAMP production.Endocrinology, 1988
In lab tests with rat brain membranes, salmon calcitonin bound amylin sites strongly compared with rat calcitonin.Molecular pharmacology, 1993

Calcitonin-salmon studies on kidneys and bladder

6 results · people 6 · animals 0 · lab 0

Top 3 of 6 results

In malignant hypercalcemia, added calcitonin was linked to a lower renal calcium reabsorption setting than APD alone.Archives of internal medicine, 1990
In normal subjects, blood sodium did not increase after rectal salmon calcitonin, whereas it increased in untreated controls.Calcified tissue international, 1987
In volunteers, nasal and suppository salmon calcitonin showed activity in the kidneys.Clinical orthopaedics and related research, 1987

Calcitonin-salmon studies on blood sugar

6 results · people 5 · animals 0 · lab 1

Top 4 of 6 results

In both groups, salmon calcitonin reduced insulin responses to glucose compared with testing without calcitonin.The Journal of clinical endocrinology and metabolism, 1981
In lab tests with rat muscle, salmon calcitonin reduced insulin-stimulated sugar incorporation into glycogen compared with insulin stimulation alone.Molecular pharmacology, 1993
In both groups, salmon calcitonin reduced C-peptide responses to glucose compared with testing without calcitonin.The Journal of clinical endocrinology and metabolism, 1981
Salmon calcitonin partly prevented glucagon suppression after glucose compared with testing without calcitonin.The Journal of clinical endocrinology and metabolism, 1981

Calcitonin-salmon studies on hormones

5 results · people 5 · animals 0 · lab 0

Top 4 of 5 results

Salmon calcitonin reduced prolactin in healthy subjects and patients with high prolactin, with maximum falls after 30--60 min.The Journal of clinical endocrinology and metabolism, 1980
In healthy subjects, salmon calcitonin reduced the TSH response to TRH compared with testing without calcitonin.The Journal of clinical endocrinology and metabolism, 1980
In healthy subjects, prolactin before TRH was lower after salmon calcitonin than without calcitonin.The Journal of clinical endocrinology and metabolism, 1980
In healthy subjects, salmon calcitonin reduced the prolactin response to TRH compared with testing without calcitonin.The Journal of clinical endocrinology and metabolism, 1980

Calcitonin-salmon studies on cancer

4 results · people 4 · animals 0 · lab 0

Top 3 of 4 results

In jaw granuloma, proportions with tumour shrinkage of at least 10% did not differ between initial calcitonin and placebo groups.International journal of oral and maxillofacial surgery, 2006
After all patients received salmon calcitonin, 7 patients with jaw granuloma had tumour shrinkage of at least 10% at 6-month follow-up.International journal of oral and maxillofacial surgery, 2006
In patients with jaw granuloma treated with salmon calcitonin, complete remission was not observed.International journal of oral and maxillofacial surgery, 2006

Calcitonin-salmon studies on stomach and gut

4 results · people 4 · animals 0 · lab 0

4 results

In normal subjects, salmon calcitonin caused intestinal water secretion, while saline did not affect absorption.The Journal of clinical endocrinology and metabolism, 1976
In acute pancreatitis, more patients had no pain and normal amylase with salmon calcitonin than with placebo.Scandinavian journal of gastroenterology, 1979
In normal subjects, salmon calcitonin caused intestinal electrolyte secretion, while saline did not affect absorption.The Journal of clinical endocrinology and metabolism, 1976
In acute pancreatitis, analgesic doses, leukocyte count, and normalization of seven criteria showed favorable nonsignificant trends with salmon calcitonin versus placebo.Scandinavian journal of gastroenterology, 1979

Calcitonin-salmon studies on mood, stress and behavior

2 results · people 2 · animals 0 · lab 0

2 results

In psychiatric inpatients, salmon calcitonin appeared to increase depression temporarily in a trial with placebo.Archives of general psychiatry, 1979
In psychiatric inpatients, salmon calcitonin appeared to reduce arousal for 24 hours in a trial with placebo.Archives of general psychiatry, 1979

Calcitonin-salmon studies on sex hormones and fertility

2 results · people 2 · animals 0 · lab 0

2 results

In endometriosis patients receiving triptoreline and calcium, estradiol did not differ between salmon calcitonin 100 IU daily and placebo.Osteoporosis international, 1995
In endometriosis patients receiving triptoreline and calcium, estradiol did not differ between salmon calcitonin 200 IU daily and placebo.Osteoporosis international, 1995

Calcitonin-salmon studies on survival and serious illness

2 results · people 2 · animals 0 · lab 0

2 results

In acute pancreatitis, salmon calcitonin did not change mortality compared with placebo.Scandinavian journal of gastroenterology, 1979
In women with postmenopausal osteoporosis, no deaths occurred during the oral rsCT, nasal ssCT, and placebo trial.Journal of bone and mineral research, 2012

Calcitonin-salmon studies on use, access and costs

2 results · people 2 · animals 0 · lab 0

2 results

In cancer-related hypercalcemia, daily furosemide dose was similar with salmon calcitonin and gallium nitrate.Annals of internal medicine, 1988
Eight calcitonin patients withdrew versus four placebo patients.Spine, 2004

Calcitonin-salmon studies on growth hormone and growth

1 result · people 1 · animals 0 · lab 0

1 result

Salmon calcitonin blocked the GH rebound at the test's end compared with testing without calcitonin.The Journal of clinical endocrinology and metabolism, 1981

Calcitonin-salmon studies on lungs and breathing

1 result · people 1 · animals 0 · lab 0

1 result

Four calcitonin patients and five calcium-only patients no longer depended on steroids.Thorax, 1994

Calcitonin-salmon studies on sleep

1 result · people 1 · animals 0 · lab 0

1 result

In psychiatric inpatients, evening salmon calcitonin appeared to delay sleep onset in a trial with placebo.Archives of general psychiatry, 1979

Calcitonin-salmon studies on weight and appetite

5 results · people 0 · animals 5 · lab 0

Top 3 of 5 results

In rats, brain-region lesions weakened but did not abolish salmon calcitonin's food intake effect compared with sham lesions.International journal of obesity and related metabolic disorders, 2001
In rats, salmon calcitonin infused into the area postrema reduced food intake for about two hours.Physiology & behavior, 2004
In rats, salmon calcitonin infused into the area postrema reduced meal size.Physiology & behavior, 2004

Trials and papers

Calcitonin-salmon trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

18 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (18 of 18)

18 trials · 1 ongoing · 14 completed · 3 stopped early · 7 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20052010201520202025

Ph 4
Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women
NCT00239889
Start Mar 2002
Ph 2
Effects of Oral Salmon Calcitonin in Human Osteoarthritis
NCT00376311
Sept 2002 to May 2004
Terminated
Terminated
Ph 3
A Study of the Treatment of Postmenopausal Women With Osteoporosis
NCT00543023
Jun 2003 to Aug 2004
Ph 3
Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
NCT00542984
Aug 2003 to Nov 2004
Ph 1
Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis
NCT00486317
Start Oct 2005
Ph 1
Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women
NCT00411125
Aug 2006 to Nov 2006
Ph 1
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
NCT00395395
Start Oct 2006
Ph 3
A Study for Patients With Osteoporosis
NCT00414973
Dec 2006 to Jul 2008
Ph 3
Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women
NCT00372099
Jan 2007 to Nov 2011
Ph 1
SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study
NCT00486369
Start Jan 2007

18 trials · 1 ongoing · 14 completed · 3 stopped early · 7 with posted results · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 4NCT03935984

Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Joseph Sferran = 3729 May 2019 to est. 31 Dec 2026

Primary Hyperparathyroidism · Hypercalcemia

Trial page ClinicalTrials.govUpdated 19 Sept 2024

CompletedPhase 4Results postedNCT03812991

The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries

University of Missouri-Columbian = 211 Jul 2019 to 28 Feb 2023

Pelvic Ring Fractures

Trial page ClinicalTrials.govUpdated 11 Jun 2024

CompletedPhase 4Results postedNCT03342001

Hypothyroidism Treated With Calcitonin

University of Maryland, Baltimoren = 1118 Jun 2018 to 14 Aug 2019

Hypothyroidism

Trial page ClinicalTrials.govUpdated 21 Feb 2022

WithdrawnPhase 4NCT00754884

Calcitonin in the Treatment of Fibromyalgia

Unidad de Investigacion en Enfermedades Cronico-Degenerativasn = 0Oct 2008 to Feb 2009

Fibromyalgia

Trial page ClinicalTrials.govUpdated 4 Dec 2015

CompletedPhase 4NCT00239889

Efficacy and Safety of Salmon Calcitonin Nasal Spray in Improving Muscle Strength and Reducing Pain After Forearm Fracture in Postmenopausal Women

Novartisn = 300Start Mar 2002

Forearm Fracture

Trial page ClinicalTrials.govUpdated 30 Nov 2006

TerminatedPhase 3Results postedNCT00704847

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

Nordic Bioscience A/Sn = 1,030Jun 2008 to Jun 2011

Osteoarthritis

Trial page ClinicalTrials.govUpdated 24 Apr 2019

CompletedPhase 3Results postedNCT00959764

A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women

Tarsa Therapeutics, Inc.n = 565Jun 2009 to Feb 2011

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 19 Nov 2013

CompletedPhase 3NCT00372099

Bone Microstructure in Nasal Salmon Calcitonin Treated Postmenopausal Women

Rene Rizzolin = 90Jan 2007 to Nov 2011

Postmenopause

Trial page ClinicalTrials.govUpdated 23 Dec 2011

CompletedPhase 3Results postedNCT00414973

A Study for Patients With Osteoporosis

Eli Lilly and Companyn = 364Dec 2006 to Jul 2008

Osteoporosis

Trial page ClinicalTrials.govUpdated 28 Oct 2009

CompletedPhase 3NCT00542984

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

Eli Lilly and Companyn = 70Aug 2003 to Nov 2004

Osteoporosis, Postmenopausal

Trial page ClinicalTrials.govUpdated 12 Oct 2007

CompletedPhase 3NCT00543023

A Study of the Treatment of Postmenopausal Women With Osteoporosis

Eli Lilly and Companyn = 104Jun 2003 to Aug 2004

Osteoporosis, Post-Menopausal

Trial page ClinicalTrials.govUpdated 12 Oct 2007

CompletedPhase 2Results postedNCT00620854

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

Tarsa Therapeutics, Inc.n = 24Feb 2008 to Apr 2008

Osteoporosis

Trial page ClinicalTrials.govUpdated 1 Feb 2012

TerminatedPhase 2NCT00376311

Effects of Oral Salmon Calcitonin in Human Osteoarthritis

Université Catholique de Louvainn = 54Sept 2002 to May 2004

Osteoarthritis

Trial page ClinicalTrials.govUpdated 14 Sept 2006

CompletedPhase 1NCT00486317

Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis

Nordic Bioscience A/SStart Oct 2005

Osteoarthritis

Trial page ClinicalTrials.govUpdated 14 Jun 2007

CompletedPhase 1NCT00486369

SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study

Nordic Bioscience A/SStart Jan 2007

Osteoarthritis

Trial page ClinicalTrials.govUpdated 14 Jun 2007

CompletedPhase 1NCT00395395

Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women

Novartisn = 56Start Oct 2006

Postmenopausal Osteoporosis

Trial page ClinicalTrials.govUpdated 28 May 2007

CompletedPhase 1NCT00411125

Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

Novartisn = 86Aug 2006 to Nov 2006

Postmenopausal Osteoporosis

Trial page ClinicalTrials.govUpdated 13 Dec 2006

CompletedNot applicableResults postedNCT01652573

Calcitonin for Treating X-linked Hypophosphatemia

Yale Universityn = 21Mar 2011 to Sept 2015

Hypophosphatemic Rickets, X Linked Dominant

Trial page ClinicalTrials.govUpdated 31 May 2017

7 more mention it but do not test it. They are not trials of Calcitonin-salmon: they only measure it (a blood level or an eligibility term) or name it in their text.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

1,643 studies match. Retracted studies are left out.

Showing 25 of 1,643 studiesquery qry_e54c3af5a8d1a9db38b9130b

Studies with results

133 studies in all, 17 on this page

In vitro (cells) · mouse · 1988

1 result

Osteoblastic cells are involved in osteoclast formation.

Takahashi et al. 1988Endocrinologycited by 646

PMID 2844518DOI 10.1210/endo-123-5-2600PUB-02844518

Full text at the publisher1 result where Calcitonin-salmon was given

Publisher page See results (1)

Randomized controlled trial · 2000

7 results

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.

3rd et al. 2000The American journal of medicinen = 817cited by 585

PMID 10996576DOI 10.1016/s0002-9343(00)00490-3PUB-10996576

Full text at the publisher7 results where Calcitonin-salmon was given

Publisher page See results (7)

In vitro (cells) · mouse · 1988

2 results

Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures.

Takahashi et al. 1988Endocrinologycited by 502

PMID 3345718DOI 10.1210/endo-122-4-1373PUB-03345718

Full text at the publisher2 results where Calcitonin-salmon was given

Publisher page See results (2)

In vitro (cells) · mouse · 1989

1 result

The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells.

Udagawa et al. 1989Endocrinologycited by 344

PMID 2676473DOI 10.1210/endo-125-4-1805PUB-02676473

Full text at the publisher1 result where Calcitonin-salmon was given

Publisher page See results (1)

Randomized controlled trial · 1993

2 results

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

Sambrook et al. 1993The New England journal of medicinecited by 280

PMID 7684512DOI 10.1056/nejm199306173282404PUB-07684512

Full text at the publisher2 results where Calcitonin-salmon was given

Publisher page See results (2)

In vitro (cells) · rabbit · 1985

1 result

The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones.

Chambers et al. 1985Endocrinologycited by 267

PMID 3880540DOI 10.1210/endo-116-1-234PUB-03880540

Full text at the publisher1 result where Calcitonin-salmon was given

Publisher page See results (1)

Randomized controlled trial · 1992

3 results

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

Overgaard et al. 1992BMJ (Clinical research ed.)cited by 228

PMID 1393035PMC1883290DOI 10.1136/bmj.305.6853.556PUB-01393035

Rights unknown3 results where Calcitonin-salmon was given

Source link See results (3)

In vitro (cells) · rabbit · 1985

1 result

Renal cytochrome P450-related arachidonate metabolite inhibits (Na+ + K+)ATPase.

Schwartzman et al. 1985Naturecited by 221

PMID 2986008DOI 10.1038/314620a0PUB-02986008

Full text at the publisher1 result where Calcitonin-salmon was given

Publisher page See results (1)

Animal study (in vivo) · rat · 2005

3 results

Transmucosal macromolecular drug delivery.

Prego et al. 2005Journal of controlled release : official journal of the Controlled Release Societycited by 194

PMID 15588901DOI 10.1016/j.jconrel.2004.07.030PUB-15588901

Full text at the publisher1 result where Calcitonin-salmon was given (plus 2 on tools or combinations, listed separately)

Publisher page See results (3)

Non-randomized trial · 1984

11 results

Long-term calcitonin therapy in postmenopausal osteoporosis.

Gruber et al. 1984Metabolism: clinical and experimentaln = 45cited by 192

PMID 6423929DOI 10.1016/0026-0495(84)90187-2PUB-06423929

Full text at the publisher11 results where Calcitonin-salmon was given

Publisher page See results (11)

Not a test of Calcitonin-salmon alone · 2006

2 results

Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree.

Prego et al. 2006Journal of controlled release : official journal of the Controlled Release Societycited by 176

PMID 16481062DOI 10.1016/j.jconrel.2005.12.015PUB-16481062

Full text at the publisher2 results where Calcitonin-salmon was a tool, carrier or part of a combination

Publisher page See results (2)

Animal study (in vivo) · rat · 2001

1 result

The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats.

Lutz et al. 2001International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesitycited by 175

PMID 11443499DOI 10.1038/sj.ijo.0801664PUB-11443499

Rights unknown1 result where Calcitonin-salmon was given

Source link See results (1)

In vitro (cells) · mouse · 1989

3 results

Prostaglandins promote osteoclastlike cell formation by a mechanism involving cyclic adenosine 3',5'-monophosphate in mouse bone marrow cell cultures.

Akatsu et al. 1989Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Researchcited by 140

PMID 2541600DOI 10.1002/jbmr.5650040106PUB-02541600

Full text at the publisher3 results where Calcitonin-salmon was given

Publisher page See results (3)

Ex vivo tissue · rat · 1993

2 results

High affinity amylin binding sites in rat brain.

Beaumont et al. 1993Molecular pharmacologycited by 137

PMID 8396712DOI 10.1016/s0026-895x(25)13212-4PUB-08396712

Full text at the publisher2 results where Calcitonin-salmon was given

Publisher page See results (2)

Randomized controlled trial · 1987

4 results

1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.

Reginster et al. 1987Lancet (London, England)n = 79cited by 136

PMID 2892047DOI 10.1016/s0140-6736(87)92619-5PUB-02892047

Full text at the publisher4 results where Calcitonin-salmon was given

Publisher page See results (4)

In vitro (cells) · chick and rat · 1987

4 results

A comparative study of disaggregated chick and rat osteoclasts in vitro: effects of calcitonin and prostaglandins.

Arnett et al. 1987Endocrinologycited by 133

PMID 3467966DOI 10.1210/endo-120-2-602PUB-03467966

Full text at the publisher4 results where Calcitonin-salmon was given

Publisher page See results (4)

Not a test of Calcitonin-salmon alone · 1980

4 results

Direct in vivo demonstration by radioautography of specific binding sites for calcitonin in skeletal and renal tissues of the rat.

Warshawsky et al. 1980The Journal of cell biologycited by 129

PMID 7391137PMC2111446DOI 10.1083/jcb.85.3.682PUB-07391137

Free to read · publisher termsCC BY-NC4 results where Calcitonin-salmon was a tool, carrier or part of a combination

Read at source See results (4)

More studies

1,493 studies in all, 8 on this page

Indexing hint: Animal study · 1986

Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization.

Nicholson et al. 1986The Journal of clinical investigationcited by 288

PMID 3016026PMC423551DOI 10.1172/jci112584PUB-03016026

Rights unknown

Source link

Indexing hint: Animal study · 1991

Expression cloning of an adenylate cyclase-coupled calcitonin receptor.

Lin et al. 1991Science (New York, N.Y.)cited by 252

PMID 1658940DOI 10.1126/science.1658940PUB-01658940

Full text at the publisher

Publisher page

PubMed tag: none · 2002

Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting.

Qvist et al. 2002Bonecited by 251

PMID 12110413DOI 10.1016/s8756-3282(02)00791-3PUB-12110413

Full text at the publisher

Publisher page

PubMed tag: Comparative Study · 1994

In vitro autoradiographic localization of amylin binding sites in rat brain.

Sexton et al. 1994Neurosciencecited by 205

PMID 7830897DOI 10.1016/0306-4522(94)90388-3PUB-07830897

Full text at the publisher

Publisher page

PubMed tag: none · 1988

Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.

Civitelli et al. 1988The Journal of clinical investigationcited by 202

PMID 3262626PMC442678DOI 10.1172/jci113725PUB-03262626

Rights unknown

Source link

PubMed tag: Comparative Study · 2005

Corrected

Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.

Hay et al. 2005Molecular pharmacologycited by 157

PMID 15692146DOI 10.1124/mol.104.008615PUB-15692146

Full text at the publisher

Publisher page Read the notice

PubMed tag: none · 2008

Trileucine improves aerosol performance and stability of spray-dried powders for inhalation.

Lechuga-Ballesteros et al. 2008Journal of pharmaceutical sciencescited by 131

PMID 17823950DOI 10.1002/jps.21078PUB-17823950

Rights unknown

Source link

PubMed tag: none · 1972

Calcitonin receptors of kidney and bone.

Marx et al. 1972Science (New York, N.Y.)cited by 125

PMID 5084670DOI 10.1126/science.178.4064.999PUB-05084670

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Calcitonin-salmon studies: 133 papers with results

Page 1 of 3

A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
Henriksen K · Bone · 2016
Randomized controlled trial · 17 results
Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.
Karsdal MA · Osteoarthritis and cartilage · 2015
Randomized controlled trial · 3 results
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Chesnut CH 3rd · The American journal of medicine · 2000
Randomized controlled trial · 7 results
Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 1994
Randomized controlled trial · 3 results
A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.
Reginster JY · European journal of clinical investigation · 1994
Randomized controlled trial · 4 results
Effect of salcatonin given intranasally on early postmenopausal bone loss.
Overgaard K · BMJ (Clinical research ed.) · 1989
Randomized controlled trial · 6 results
The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain.
Ofluoglu D · Clinical rheumatology · 2007
Randomized controlled trial · 3 results
Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
Karsdal MA · BMC clinical pharmacology · 2008
Randomized controlled trial · 5 results
A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012
Randomized controlled trial · 11 results
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2004
Randomized controlled trial · 13 results
Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.
Bagger YZ · Bone · 2005
Randomized controlled trial · 3 results
Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
Binkley N · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014
Randomized controlled trial · 6 results
Salmon calcitonin in the prevention of bone loss at perimenopause.
Arnala I · Bone · 1996
Randomized controlled trial · 2 results
Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
Ellerington MC · Calcified tissue international · 1996
Randomized controlled trial · 8 results
The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis.
Papadokostakis G · European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2006
Randomized controlled trial · 6 results
A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.
Kung AW · Current medical research and opinion · 2006
Randomized controlled trial · 20 results
A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis.
Goebell H · Scandinavian journal of gastroenterology · 1979
Randomized controlled trial · 3 results
Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
Overgaard K · Calcified tissue international · 1994
Randomized controlled trial · 7 results
Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E · Clinical rheumatology · 2005
Randomized controlled trial · 8 results
Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K · Clinical therapeutics · 1995
Randomized controlled trial · 2 results
1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin.
Reginster JY · Lancet (London, England) · 1987
Randomized controlled trial · 4 results
The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study.
Tóth E · Bone · 2005
Randomized controlled trial · 5 results
The effect of adding calcitonin to physical treatment on reflex sympathetic dystrophy.
Gobelet C · Pain · 1992
Randomized controlled trial · 4 results
Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis.
Hwang JS · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2006
Randomized controlled trial · 10 results
A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis.
Hay JE · Journal of hepatology · 2001
Randomized controlled trial · 3 results
Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
Thamsborg G · Bone · 1996
Randomized controlled trial · 9 results
Postoperative analgesia induced by subarachnoid lidocaine plus calcitonin.
Miralles FS · Anesthesia and analgesia · 1987
Randomized controlled trial · 2 results
Effectiveness of salmon calcitonin nasal spray in the treatment of lumbar canal stenosis: a double-blind, randomized, placebo-controlled, parallel group trial.
Podichetty VK · Spine · 2004
Randomized controlled trial · 6 results
Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin.
Warrell RP Jr · Annals of internal medicine · 1988
Randomized controlled trial · 4 results
Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis.
Dursun N · International journal of clinical practice · 2001
Randomized controlled trial · 6 results
The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial.
Karachalios T · The Journal of bone and joint surgery. British volume · 2004
Randomized controlled trial · 6 results
The efficacy of physical therapy and physical therapy plus calcitonin in the treatment of lumbar spinal stenosis.
Sahin F · Yonsei medical journal · 2009
Randomized controlled trial · 3 results
Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.
Luengo M · Thorax · 1994
Randomized controlled trial · 7 results
Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin.
Karsdal MA · BMC clinical pharmacology · 2008
Randomized controlled trial · 6 results
A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.
Healey JH · Calcified tissue international · 1996
Randomized controlled trial · 2 results
Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study.
Lyritis GP · The Clinical journal of pain · 1999
Randomized controlled trial · 9 results
Analgetic activity of calcitonin in patients with painful osteolytic metastases of breast cancer. Results of a controlled randomized study.
Roth A · Oncology · 1986
Randomized controlled trial · 9 results
Randomised placebo-controlled trial on the effectiveness of nasal salmon calcitonin in the treatment of lumbar spinal stenosis.
Tafazal SI · European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2007
Randomized controlled trial · 5 results
A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin.
Karsdal MA · Journal of clinical pharmacology · 2009
Randomized controlled trial · 4 results
Efficacy of salmon calcitonin in complex regional pain syndrome (type 1) in addition to physical therapy.
Sahin F · Clinical rheumatology · 2006
Randomized controlled trial · 1 result
A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
Trovas GP · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2002
Randomized controlled trial · 4 results
A double-blind controlled trial of salmon calcitonin in pain due to malignancy.
Hindley AC · Cancer chemotherapy and pharmacology · 1982
Randomized controlled trial · 2 results
An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
Gennari C · Calcified tissue international · 1992
Randomized controlled trial · 5 results
Calcitonin, a diabetogenic hormone?
Passariello N · The Journal of clinical endocrinology and metabolism · 1981
Randomized controlled trial · 6 results
Calcitonin therapy in central giant cell granuloma of the jaw: a randomized double-blind placebo-controlled study.
de Lange J · International journal of oral and maxillofacial surgery · 2006
Randomized controlled trial · 4 results
Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
Sambrook P · The New England journal of medicine · 1993
Randomized controlled trial · 2 results
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
Overgaard K · BMJ (Clinical research ed.) · 1992
Randomized controlled trial · 3 results
The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.
Karsdal MA · Osteoarthritis and cartilage · 2010
Randomized controlled trial · 7 results
Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.
Hodsman AB · Bone and mineral · 1991
Randomized controlled trial · 3 results
A prospective randomized study for prevention of postrenal transplantation bone loss.
El-Agroudy AE · Kidney international · 2005
Randomized controlled trial · 5 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	Calcitonin salmon nasal spray (Apotex)	27 Oct 2026	dailymed.nlm.nih.gov (opens in a new tab)
EU	EMA	Nationally authorised calcitonin-containing injectable medicines	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Not listed as banned by WADA The substance is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

58 safety results for Calcitonin-salmon.

Human evidence· 58

In postmenopausal osteoporosis, approximately 92% of each group experienced adverse events, mostly mild or moderate.
Randomized controlled trialn = 4,665
Subjects with any adverse event
≈ 92%
each treatment group
In postmenopausal osteoporosis, approximately 80% in each oral rsCT, nasal ssCT, and placebo group experienced adverse events, mostly mild or moderate.
Randomized controlled trialn = 565
Proportion with any adverse event
≈ 80%
each treatment group
In postmenopausal women with low bone mass, calcitonin and placebo had comparable overall safety profiles.
Randomized controlled trialn = 129
In postmenopausal Asian women with osteoporosis, adverse event rates were similar with salmon calcitonin and teriparatide.
Randomized controlled trialn = 104
In acute pancreatitis, salmon calcitonin did not influence mortality versus placebo, with overall mortality of 5.3%.
Randomized controlled trialn = 94
Overall mortality
5.3%
both groups combined
In men with idiopathic osteoporosis, no premature discontinuations were reported with calcitonin nasal spray in this trial, compared with the control group.
Randomized controlled trialn = 71
In steroid-dependent asthmatic patients, five patients in each group withdrew during the second year.
Randomized controlled trialn = 44
Second-year dropouts
5 patients
calcitonin group
Second-year dropouts
5 patients
calcium alone group
In patients with vertebral fractures, general safety was comparable between nasal and subcutaneous calcitonin.
Non-randomized trialn = 204

The top 24 of 58 results.

Doses studied · 143

The doses that these studies used. They are not recommendations.

0.8 mg/dayHuman
Species
human
Route
oral
Duration
36 months
Design
Randomized controlled trial · n = 4,665
0.8 mg twice dailyHuman
Species
human
Route
oral
Duration
24 months
Design
Randomized controlled trial · n = 1,176
200 IU dailyHuman
Species
human
Route
intranasal
Duration
5 years
Design
Randomized controlled trial · n = 557
50 IU/day, 5 days per weekHuman
Species
human
Route
intranasal
Duration
3 years
Design
Randomized controlled trial · n = 186
50 IU daily, 5 days per weekHuman
Species
human
Route
intranasal
Duration
5 years
Design
Randomized controlled trial · n = 87
100 IUHuman
Species
human
Route
intranasal
Duration
1 year
Design
Randomized controlled trial

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
0.8 mg/day	Human	human	oral	36 months	Randomized controlled trial · n = 4,665
0.8 mg twice daily	Human	human	oral	24 months	Randomized controlled trial · n = 1,176
200 IU daily	Human	human	intranasal	5 years	Randomized controlled trial · n = 557
50 IU/day, 5 days per week	Human	human	intranasal	3 years	Randomized controlled trial · n = 186
50 IU daily, 5 days per week	Human	human	intranasal	5 years	Randomized controlled trial · n = 87
100 IU	Human	human	intranasal	1 year	Randomized controlled trial

6 of 143 shown

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000121
Peptide version: 2
Peptide hash: 00187be81409dfb0…
Data version: 308560

Latest changes

28 Oct 2026UpdatedData version 304177
27 Oct 2026CreatedData version 256650

For developers

curl -s https://pepbank.io/v1/briefs/calcitonin-salmon

Evidence summary for Calcitonin-salmon: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Bone and jointMusculoskeletal	Human: 346 results from 84 studies: 103 increase, 111 decrease, 94 no significant change, 2 mixed, 36 not reported. Strongest design: Randomized controlled trial	Animal: 4 results from 2 studies: 3 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	Lab: 11 results from 5 studies: 2 increase, 6 decrease, 1 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	361
PainNervous system and cognition	Human: 52 results from 23 studies: 7 increase, 26 decrease, 12 no significant change, 7 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	52
PharmacokineticsRespiratory	Human: 49 results from 15 studies: 9 increase, 8 decrease, 7 no significant change, 1 mixed, 24 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	49
Adverse eventsWhole body	Human: 42 results from 23 studies: 2 increase, 3 no significant change, 37 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	42
Exercise and physical functionMusculoskeletal	Human: 28 results from 13 studies: 9 increase, 2 decrease, 15 no significant change, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	28
Electrolyte balanceKidney and urinary	Human: 15 results from 4 studies: 6 increase, 7 decrease, 2 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	15
Gastrointestinal adverse eventsGastrointestinal	Human: 13 results from 9 studies: 1 increase, 12 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	13
Receptor activity and mechanismPharmacology	Human: 12 results from 3 studies: 5 increase, 1 no significant change, 6 not reported. Strongest design: Non-randomized trial	No results	Lab: 21 results from 8 studies: 11 increase, 1 decrease, 4 no significant change, 1 mixed, 4 not reported. Strongest design: Ex vivo tissue	No results	33
Calcium MetabolismKidney and urinary	Human: 11 results from 3 studies: 2 increase, 4 decrease, 4 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	11
Mineral metabolismNervous system and cognition	Human: 11 results from 3 studies: 1 increase, 5 decrease, 4 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	11
Kidney functionKidney and urinary	Human: 6 results from 3 studies: 2 increase, 1 decrease, 2 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	6
Glycemic controlMetabolic and weight	Human: 5 results from 1 study: 2 increase, 3 decrease. Strongest design: Randomized controlled trial	No results	Lab: 1 result from 1 study: 1 decrease. Strongest design: Ex vivo tissue	No results	6

Outcome group	Human	Animal	Lab	Computer model	Total
Bone and jointMusculoskeletal	Human: 346 results from 84 studies: 103 increase, 111 decrease, 94 no significant change, 2 mixed, 36 not reported. Strongest design: Randomized controlled trial	Animal: 4 results from 2 studies: 3 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	Lab: 11 results from 5 studies: 2 increase, 6 decrease, 1 no significant change, 2 not reported. Strongest design: In vitro (cells)	No results	361
PainNervous system and cognition	Human: 52 results from 23 studies: 7 increase, 26 decrease, 12 no significant change, 7 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	52
PharmacokineticsRespiratory	Human: 49 results from 15 studies: 9 increase, 8 decrease, 7 no significant change, 1 mixed, 24 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	49
Adverse eventsWhole body	Human: 42 results from 23 studies: 2 increase, 3 no significant change, 37 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	42
Exercise and physical functionMusculoskeletal	Human: 28 results from 13 studies: 9 increase, 2 decrease, 15 no significant change, 2 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	28
Electrolyte balanceKidney and urinary	Human: 15 results from 4 studies: 6 increase, 7 decrease, 2 no significant change. Strongest design: Randomized controlled trial	No results	No results	No results	15
Gastrointestinal adverse eventsGastrointestinal	Human: 13 results from 9 studies: 1 increase, 12 not reported. Strongest design: Randomized controlled trial	No results	No results	No results	13
Receptor activity and mechanismPharmacology	Human: 12 results from 3 studies: 5 increase, 1 no significant change, 6 not reported. Strongest design: Non-randomized trial	No results	Lab: 21 results from 8 studies: 11 increase, 1 decrease, 4 no significant change, 1 mixed, 4 not reported. Strongest design: Ex vivo tissue	No results	33
Calcium MetabolismKidney and urinary	Human: 11 results from 3 studies: 2 increase, 4 decrease, 4 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	11
Mineral metabolismNervous system and cognition	Human: 11 results from 3 studies: 1 increase, 5 decrease, 4 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	11
Kidney functionKidney and urinary	Human: 6 results from 3 studies: 2 increase, 1 decrease, 2 no significant change, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	6
Glycemic controlMetabolic and weight	Human: 5 results from 1 study: 2 increase, 3 decrease. Strongest design: Randomized controlled trial	No results	Lab: 1 result from 1 study: 1 decrease. Strongest design: Ex vivo tissue	No results	6